Pharmaceutical Value proposition
We have merged with Bristol Myers Squibb creating a leading biopharma company, ideally positioned to discover, develop and deliver innovative medicines for patients fighting serious diseases. Visit www.bms.com to continue to learn more about our work to produce the next generation of medicines to treat cancer and other serious diseases.
For more information on the acquisition, see our press release at: http://bit.ly/3UbQcnl
Hematology, Oncology, Inflammation, Immunology, Cancer, R&D, Innovation, Immunooncology, biopharma, Epigenetics, Protein Homeostasis, Translation Medicine, and Orphan diseases
Global Biopharmaceutical Company - Bristol Myers Squibb
Global Biopharmaceutical Company - Bristol Myers Squibb
https://www.bms.com/
| Entity | Type | Tweets | Articles | |
|---|---|---|---|---|
 | Les Echos Etudes constructiontech, agritech, Market Research, healthtech, martech, transporttech | Other 28 Jun 2024 | | |
 | CellProthera SAS biotech, deeptech, Biotechnology Research | Other 7 Mar 2024 | | |
 | JEITO Venture Capital and Private Equity Principals | Other 5 Jan 2024 | | |
 | Airfinity Ltd biotech, Information Services, deeptech, healthtech | Other 8 Aug 2023 | | |
 | Center for Genomic Interpretation biotech, deeptech, Hospitals and Health Care | Other 31 Jul 2023 | | |
 | BioPharma Asia Magazine Book and Periodical Publishing | Other 31 Jul 2022 | | |
 | HealthBeacon healthtech, Wellness and Fitness Services | Other 14 Oct 2022 | | |
 | libheros healthtech, Hospitals and Health Care | Other 29 Dec 2022 | | |